Money Peak: Healthcare Sector Report

March 25 – April 1, 2026

🔍 Market Overview

The healthcare sector advanced by +1.78% this reporting week, positioning itself mid-range among the eleven S&P 500 sectors – significantly trailing the technology sector (+3.04%) and communication services (+3.45%), yet ahead of defensive areas such as consumer staples (–0.02%) and energy (+0.23%). This weekly gain is not a random occurrence: The sector benefited from strategic capital rotation by institutional investors seeking refuge in less economically sensitive areas amid ongoing geopolitical tensions and trade policy uncertainties.

Within the sector, performance was mixed. Pharmaceutical companies and biotech firms with strong pipeline dynamics took the lead, whereas health insurers – particularly UnitedHealth Group – were impacted by regulatory pressures and rising cost ratios. The fundamental basis remains robust: the sector recently achieved a year-over-year revenue growth of 10.4%, exceeding consensus expectations by approximately 260 basis points – the strongest surprise effect among all S&P 500 sectors. Additionally, valuations remain historically low, rendering healthcare increasingly appealing as an investment alternative.

📊 Current Key Figures of Major Sector Players

The following table provides an overview of the key data for the five largest sector representatives in the reporting week:

*AbbVie's high P/E ratio reflects extraordinary burdens from acquisitions; the operational cash flow profile is significantly more stable.

💊 Pharma & Biotechnology: Pipeline as a Price Driver

The pharma and biotech segment remained the most dynamic part of the sector this week. Notably, Merck & Co. attracted attention: the company presented data from its oral PCSK9 inhibitor Enlicitide Decanoate, which in a late-stage study lowered LDL cholesterol levels by an impressive 64.6% – significantly more than the tested oral non-statin therapies. Should this drug receive approval, it could become one of the most important blockbusters in Merck’s portfolio. The stock price reacted positively, with Merck approaching its 52-week high of $125.14.

Concurrently, Merck entered a research agreement with biotech firm Infinimmune, which could bring the company potential milestone payments of up to $838 million. Such strategic partnerships are typical for pharmaceutical companies, which complement their pipeline cost-effectively with external expertise.

AbbVie Inc. presented new clinical data on its dermatology pipeline at the American Academy of Dermatology's annual meeting. According to analyst consensus, Risankizumab (Skyrizi) and Upadacitinib (Rinvoq) are expected to drive double-digit revenue growth in 2026, more than offsetting the gradual decline in Humira revenues. The announcement of a Q1-2026 earnings report scheduled for April 29 could further draw investor attention to AbbVie. AbbVie's strong operational cash flow generation – around $10.50 per share on a TTM basis – underscores the solidity of the business model despite the currently balance-sheet-burdened equity structure.

In the biotechnology sector, progress in the global development program for JNJ-1900 (NBTXR3) – a radiotherapy enhancer licensed by Nanobiotix to Johnson & Johnson – attracted positive attention. Clinical data in head and neck tumors, esophageal, pancreatic, and lung cancers were published, bolstering this compound’s potential in oncology.

🏥 Managed Care: Short-term Recovery, Structural Risks Persist

UnitedHealth Group rebounded significantly this week by +3.36% to $270.59 – after the price had fallen by –3.37% on Thursday. This fluctuation illustrates the tense situation: The Ninth Circuit Court of Appeals in the US is soon to decide on a landmark Medicare Advantage fraud case that could redefine the company's legal immunity.

Fundamentally, UnitedHealth remains a giant with a market capitalization of approximately $246 billion and annual revenues reaching almost $492 per share. However, the medical care ratio (MCR) is under pressure, and the P/E ratio of 20.4x is historically low – the 52-week high is $606.36, with the current price almost 55% below that. The company pays a dividend of $8.84 per share (yield: ~3.27%), providing at least an income support amidst ongoing regulatory risks.

🛡️ Defensive Quality Stocks: J&J and Pfizer

Johnson & Johnson reaffirmed this week its status as a reliable dividend stock. With 63 consecutive years of dividend increases, J&J belongs to the few so-called "Dividend Kings" on Wall Street. The stock price rose by +0.80% to $244.44, close to the 50-day moving average of $237.37 – a technical signal for regained upward momentum. The P/E ratio of 22.1x and a dividend yield of 2.13% are acceptable for such a stable business model.

Pfizer Inc. presents itself as the counterpart: attractively valued but with an increased risk profile. The price increased by +1.12% to $28.08, reaching a new 52-week high. The dividend yield of over 6% is tempting, yet the payout ratio currently exceeds earnings (Payout Ratio TTM: 125.75%). The cancer pipeline portfolio – particularly Padcev, Lorbrena, and Talzenna (revenue growth: +81.5% YoY) – provides arguments for a mid-term recovery. However, regulatory risks surrounding US drug pricing policy (so-called “Most-Favored-Nation” model) remain a relevant uncertainty factor.

⚠️ Challenges and Structural Risks

In addition to regulatory pressure in the managed care sector, two structural risks merit special attention:

Pricing policy and trade policy uncertainty: The US government is considering introducing price caps for medications. Should the “Most-Favored-Nation” model be more broadly implemented, margins, particularly for Pfizer and Merck, could come under pressure. Simultaneously, global tariffs – recently raised to 10% – drive up costs for imported active ingredients and precursors.

Supply chain vulnerabilities: Companies with a high import share of active ingredients have begun relocating production capacities to the US. These investments support supply security in the medium term but burden the capital budget and margins in the short term.

💡 Strategic Insights for Investors

The following information is intended solely for general information and illustration of possible market scenarios. It does not constitute individual investment advice. Please always consider your personal risk tolerance and consult a qualified financial advisor if needed.

1. Observe pharma with strong pipelines: Companies like Merck, which achieve clinical milestones in high-growth indications (cholesterol, oncology), could benefit mid-term from approval successes and associated revenue boosts. Investors already invested in the healthcare sector should keep an eye on pipeline events – these can trigger significant short-term price movements.

2. Distinguish between dividend quality and yield: A high dividend yield alone is not a buy signal. Pfizer’s payout ratio is significantly above earnings, posing a long-term risk of a cut. In contrast, Johnson & Johnson’s 63-year dividend history is underpinned by a healthy payout ratio of ~46% – a qualitative difference that may matter to income-oriented investors.

3. Approach managed care with caution: UnitedHealth is trading well below its historical highs and has an attractive valuation. Simultaneously, ongoing legal risks and rising cost ratios are real factors that could weigh on the short-term price outlook. Investors should closely monitor the outcome of the ongoing appeal process and the quarterly report on April 21.

4. Strategically utilize defensive sector properties: In a market environment of increased volatility – the CNN Fear & Greed Index recently stood at 13 (Extreme Fear) – the healthcare sector has historically assumed a stabilizing function within portfolios. This is illustratively an overall market phenomenon, not a personal recommendation for portfolio weighting.

5. Earnings season in April as the next catalyst: Johnson & Johnson reports on April 14, UnitedHealth on April 21, Merck on April 30. These events are likely to set the direction for the entire sector in the short term and should be closely watched by investors with healthcare exposure.

This report was prepared by Money Peak based on publicly available market and company data. It is intended solely for informational purposes and does not constitute individual investment advice under the German Banking Act (KWG) or BaFin regulations. Investment decisions should always be based on one’s personal financial situation and after consulting a licensed financial advisor.